In vivo drug distribution dynamics in thermoablated and normal rabbit livers from biodegradable polymers.
Image-guided radiofrequency ablation combined with intratumoral drug delivery provides a novel and minimally invasive treatment of liver cancers. In this study, the in vivo transport properties of doxorubicin in thermoablated and nonablated rabbit livers were characterized and compared. Doxorubicin was released from polymer implants (millirods) to the ablated and nonablated liver tissue. At different time points, the 2D distribution profiles were quantitatively determined by a fluorescence imaging method. Analysis of the doxorubicin concentration at the ablation boundary showed that it reached a maximum of 49.8 microg/g at 24 h after implantation, which was higher than the reported cytotoxic concentration of doxorubicin (6.4 microg/g) for liver VX-2 cancer cells. This value dropped to 0.4 microg/g at 48 h after implantation due to the depletion of doxorubicin from the polymer millirod. Results also showed that the area of drug distribution was significantly larger in ablated tissue than nonablated tissue. The therapeutic penetration distance was found to be 5.2 mm in thermoablated livers, compared to 1.2 mm in nonablated livers at 24 h. This difference in drug transport properties is attributed to destruction of the vasculature network in the ablated tissue as supported by histological analysis. Consequently, drug washout by blood perfusion is hampered while drug diffusion becomes the dominant process of transport in the ablated tissue. Results from this study provide insightful information on the rational design and development of polymer millirods for intratumoral drug delivery applications.
Gao
Jinming
J
Cancer-Targeted Drug Delivery Laboratory, Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, USA. jmg23@po.cwru.edu
Qian
Feng
F
Szymanski-Exner
Agata
A
Stowe
Nicholas
N
Haaga
John
J
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000378:metabolism / Q000493:pharmacokinetics; D001672:Biocompatible Materials / Q000378:metabolism*; D004317:Doxorubicin / Q000378:metabolism / Q000493:pharmacokinetics; D004343:Drug Implants; D006358:Hot Temperature; D066298:In Vitro Techniques; D007700:Kinetics; D008099:Liver / Q000033:anatomy & histology / Q000378:metabolism* / Q000502:physiology*; D008970:Molecular Weight; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D011098:Polyglactin 910 / Q000737:chemistry; D011817:Rabbits; D014018:Tissue Distribution; D014783:Viscosity
D000903:Antibiotics, Antineoplastic; D001672:Biocompatible Materials; D004343:Drug Implants; D004364:Pharmaceutical Preparations; D011098:Polyglactin 910; D004317:Doxorubicin